Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lung Carcinomas with EGFR

Lung Carcinomas with EGFR LETTERS TO THE EDITOR 18 adenosquamous tumors, 733 LCs Aglaya G. Iyevleva, MD, PhD Lung Carcinomas  with unknown histological information N.N. Petrov Institute of Oncology with EGFR Exon 19  or rare histological types). In addition St. Petersburg, Russia to 455 common mutations (288 ex19del St.Petersburg Pediatric Insertions Are Sensitive  and 167 L858R), we were able to iden- Medical Academy tify four patients with insertions lead- to Gefitinib Treatment St.Petersburg, Russia ing to identical amino acid changes (Fig. 2). All patients were nonsmoking To the Editor: Natalia V. Mitiushkina, PhD women with lung adenocarcinomas, Lung carcinomas (LCs) are character- and three of them received gefitinib N.N. Petrov Institute of Oncology ized by frequent occurrence of epider- at a standard dose 250 mg/day. Patient St. Petersburg, Russia mal growth factor receptor (EGFR) 1, 56 years old, received first-line pal- mutations conferring pronounced sen- liative gefitinib treatment for postsur - Nina A. Karaseva, MD, PhD sitivity of the tumors to EGFR tyrosine gical LC relapse, and showed 70% City Oncological Hospital kinase inhibitors (TKIs). Exon 19 dele- reduction of tumor mass, which was St. Petersburg, Russia tions (ex19del) and codon 858 substitu- classified as partial response accord- tions (L858R) constitute the majority of ing to Response Evaluation Criteria known TKI-sensitizing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Lung Carcinomas with EGFR

Imyanitov, Evgeny N.
Journal of Thoracic Oncology , Volume 9 (4) – Apr 1, 2014
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/lung-carcinomas-with-egfr-VnoBJ4vSsn

References (5)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000106
pmid
24736087
Publisher site
See Article on Publisher Site

Abstract

LETTERS TO THE EDITOR 18 adenosquamous tumors, 733 LCs Aglaya G. Iyevleva, MD, PhD Lung Carcinomas  with unknown histological information N.N. Petrov Institute of Oncology with EGFR Exon 19  or rare histological types). In addition St. Petersburg, Russia to 455 common mutations (288 ex19del St.Petersburg Pediatric Insertions Are Sensitive  and 167 L858R), we were able to iden- Medical Academy tify four patients with insertions lead- to Gefitinib Treatment St.Petersburg, Russia ing to identical amino acid changes (Fig. 2). All patients were nonsmoking To the Editor: Natalia V. Mitiushkina, PhD women with lung adenocarcinomas, Lung carcinomas (LCs) are character- and three of them received gefitinib N.N. Petrov Institute of Oncology ized by frequent occurrence of epider- at a standard dose 250 mg/day. Patient St. Petersburg, Russia mal growth factor receptor (EGFR) 1, 56 years old, received first-line pal- mutations conferring pronounced sen- liative gefitinib treatment for postsur - Nina A. Karaseva, MD, PhD sitivity of the tumors to EGFR tyrosine gical LC relapse, and showed 70% City Oncological Hospital kinase inhibitors (TKIs). Exon 19 dele- reduction of tumor mass, which was St. Petersburg, Russia tions (ex19del) and codon 858 substitu- classified as partial response accord- tions (L858R) constitute the majority of ing to Response Evaluation Criteria known TKI-sensitizing

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Apr 1, 2014

There are no references for this article.